Processing

Please wait...

Settings

Settings

1. WO2017108737 - 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS

Publication Number WO/2017/108737
Publication Date 29.06.2017
International Application No. PCT/EP2016/081837
International Filing Date 20.12.2016
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
06
Antiasthmatics
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 11/00 (2006.01)
A61P 11/06 (2006.01)
CPC
C07D 471/04
Applicants
  • CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A 43122 Parma, IT
Inventors
  • CAPALDI, Carmelida; IT
  • ARMANI, Elisabetta; IT
  • JENNINGS, Andrew Stephen Robert; IT
  • HURLEY, Christopher; IT
Agents
  • MINOJA, Fabrizio; IT
Priority Data
15202348.723.12.2015EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS
(FR) DÉRIVÉS DE 1-(3-TERT-BUTYL-PHÉNYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TÉTRAHYDRO-NAPHTHALÈN-1-YL)-URÉE ET LEUR UTILISATION EN TANT QU'INHIBITEUR DE P38 MAPK
Abstract
(EN)
This invention relates to compounds of formula (I) wherein R1 is H or selected from the group consisting of (C1-C4)alkyl-, (C3- C7)cycloalkyl-, (C4-C7)heterocycloalkyl-, RAO-, RCSO2(RA)N-, RCSO2-, (RARB)NC(O)-, RCCO(RA)N-, RAO(C1-C4)alkylene-, (RARB)N-, RCO(O) C-, (RARB)NSO2-, RCSO2(C1-C4)alkylene-, RC(O)CO(C1-C4)alkylene-, RCSO2(RA)N(C1-C4)alkylene-, RCOC(O)(RA)N-, (RARB)NCO(RD)N-, (RARB) N(C1-C6)alkylene-, wherein any of such alkyl, alkylene, cycloalkyl, heterocycloalkyl or heteroaryl may be optionally substituted by one or more groups selected from (C1-C3)alkyl, (C3-C6)cycloalkyl, (C4-C7) heterocycloalkyl, -ORA, halo and CN; R2 is H or selected from the group consisting of halo, (C1-C6)alkyl, RAO-, (RARB)N(C1-C6)alkylene- and RAO(C1-C4)alkylene-; R3 is selected from (lla)-(llf) and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
(FR)
La présente invention concerne des composés de formule (I), où R1 représente H ou est choisi dans le groupe constitué par un groupe (C1-C4)alkyle-, (C3-C7)cycloalkyle-, (C4-C7)hétérocycloalkyle-, RAO-, RCSO2(RA)N-, RCSO2-, (RARB)NC(O)-, RCCO(RA)N-, RAO(C1-C4)alkylène-, (RARB)N-, RCO(O) C-, (RARB)NSO2-, RCSO2(C1-C4)alkylène-, RC(O)CO(C1-C4)alkylène-, RCSO2(RA)N(C1-C4)alkylène-, RCOC(O)(RA)N-, (RARB)NCO(RD)N-, (RARB) N(C1-C6)alkylène-, l'un quelconque des groupes alkyle, alkylène, cycloalkyle, hétérocycloalkyle ou hétéroaryle peut être éventuellement substitué par un ou plusieurs groupes choisis parmi les groupes (C1-C3)alkyle, (C3-C6)cycloalkyle, (C4-C7) hétérocycloalkyle, -ORA, un atome d'halogène et CN ; R2 représente H ou est choisi dans le groupe constitué par un atome d'halogène, un groupe (C1-C6)alkyle, RAO-, (RARB)N(C1-C6)alkylène- et RAO(C1-C4)alkylène- ; R3 est choisi dans le groupe constitué par (IIa)-(IIf) et des compositions qui sont des inhibiteurs de p38 MAPK, utiles en tant qu'agents anti-inflammatoires dans le traitement, entre autres, de maladies des voies respiratoires.
Also published as
Latest bibliographic data on file with the International Bureau